Aims: This meta-analysis aims to evaluate the effects of common polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene on the toxicity and clinical responses of irinotecan-based chemotherapy in patients with colorectal cancer (CRC). Methods: The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library, and CBM databases were searched from their inception through November 1st, 2013 without language restrictions. Meta-analysis was conducted with the use of the STATA 12.0 software. Crude odds ratios (ORs) and their 95% confidence intervals (95% CIs) were calculated. Seven clinical cohort studies with a total of 815 CRC patients met the inclusion criteria. Two common polymorphisms (677 C>T and 1298 A>C) in the MTHFR gene were assessed. Results: The results from our meta-analysis suggested that MTHFR genetic polymorphisms might significantly decrease the rate of grade 3/4 toxicity of irinotecan-based chemotherapy in CRC patients (OR=0.53, 95% CI: 0.32-0.89, p=0.015). Furthermore, we also demonstrated that MTHFR genetic polymorphisms strongly correlated with good clinical responses (complete response+partial response) to irinotecan-based chemotherapy in CRC patients (OR=1.47, 95% CI: 1.05-2.04, p=0.024). Conclusions: Our findings provide empirical evidence that MTHFR genetic polymorphisms may decrease the toxicity of irinotecan-based chemotherapy and increase the clinical benefits for CRC patients. Thus, MTHFR genetic polymorphisms may be screened to predict the clinical responses to irinotecan-based chemotherapy in CRC patients.
Get full access to this article
View all access options for this article.
References
1.
AkogluB, MilovicV, CasparyWF, et al. (2004) Hyperproliferation of homocysteine-treated colon cancer cells is reversed by folate and 5-methyltetrahydrofolate. Eur J Nutr, 43:93-99.
2.
ArnesenE, RefsumH, BonaaKH, et al. (1995) Serum total homocysteine and coronary heart disease. Int J Epidemiol, 24:704-709.
3.
BannaGL, CollovaE, GebbiaV, et al. (2010) Anticancer oral therapy: emerging related issues. Cancer Treat Rev, 36:595-605.
4.
BottoLD, YangQ (2000) 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol, 151:862-877.
5.
BraunMS, RichmanSD, ThompsonL, et al. (2009) Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol, 27:5519-5528.
6.
BudaiB, KomlosiV, AdleffV, et al. (2012) Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab. Pharmacogenet Genomics, 22:69-72.
7.
Castillo-FernandezO, SantibanezM, BauzaA, et al. (2010) Methylenetetrahydrofolate reductase polymorphism (677 C>T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid. Arch Med Res, 41:430-435.
8.
ChenS, YuehMF, BigoC, et al. (2013) Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11). Proc Natl Acad Sci U S A, 110:19143-19148.
9.
ChoiSW, MasonJB (2002) Folate status: effects on pathways of colorectal carcinogenesis. J Nutr, 132:2413S-2418S.
10.
CortejosoL, Lopez-FernandezLA (2012) Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. Pharmacogenomics, 13:1173-1191.
11.
CuiLH, ShinMH, KweonSS, et al. (2010) Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer in a Korean population. BMC Cancer, 10:236
12.
CurtinK, BiglerJ, SlatteryML, et al. (2004) MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev, 13:285-292.
13.
EisenhauerEA, TherasseP, BogaertsJ, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45:228-247.
14.
ForgesT, CheryC, AudonnetS, et al. (2010) Life-threatening methylenetetrahydrofolate reductase (MTHFR) deficiency with extremely early onset: characterization of two novel mutations in compound heterozygous patients. Mol Genet Metab, 100:143-148.
15.
GlimeliusB, GarmoH, BerglundA, et al. (2011) Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J, 11:61-71.
16.
GonenN, AssarafYG (2012) Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat, 15:183-210.
17.
KatoI, DnistrianAM, SchwartzM, et al. (1999) Serum folate, homocysteine and colorectal cancer risk in women: a nested case-control study. Br J Cancer, 79:1917-1922.
18.
KawakamiK, RuszkiewiczA, BennettG, et al. (2003) The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res, 9:5860-5865.
19.
LaBonteMJ, ManegoldPC, WilsonPM, et al. (2009) The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Int J Cancer, 125:2957-2969.
20.
LiR, WangR, LiY, et al. (2013) Association study on MTHFR polymorphisms and meningioma in northern China. Gene, 516:291-293.
21.
LiewSC, Das-GuptaE, WongSF, et al. (2012) Association of methylentetraydrofolate reductase (MTHFR) 677 C>T gene polymorphism and homocysteine levels in psoriasis vulgaris patients from Malaysia: a case-control study. Nutr J, 11:1
22.
MarcuelloE, AltesA, MenoyoA, et al. (2006) Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?. Cancer Chemother Pharmacol, 57:835-840.
23.
MassacesiC, TerrazzinoS, MarcucciF, et al. (2006) Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer, 106:1007-1016.
24.
OttK, RachakondaPS, PanzramB, et al. (2011) DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol, 18:2688-2698.
25.
PetersJL, SuttonAJ, JonesDR, et al. (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295:676-680.
26.
RuzzoA, GrazianoF, LoupakisF, et al. (2008) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J, 8:278-288.
27.
SameerAS, ShahZA, NissarS, et al. (2011) Risk of colorectal cancer associated with the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in the Kashmiri population. Genet Mol Res, 10:1200-1210.
28.
ShulmanK, CohenI, Barnett-GrinessO, et al. (2011) Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer, 117:3156-3162.
29.
SohdaS, ArinamiT, HamadaH, et al. (1997) Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet, 34:525-526.
30.
StangA (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25:603-605.
31.
StankovaJ, LawranceAK, RozenR (2008) Methylenetetrahydrofolate reductase (MTHFR): a novel target for cancer therapy. Curr Pharm Des, 14:1143-1150.
32.
StoccoG, CrewsKR, EvansWE (2010) Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin Drug Saf, 9:23-37.
33.
SwamiU, GoelS, ManiS (2013) Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. Curr Drug Targets, 14:777-797.
34.
ThomasF, Motsinger-ReifAA, HoskinsJM, et al. (2011) Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer, 105:1654-1662.
35.
ToffoliG, CecchinE (2004) Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy. J Chemother, 16Suppl 4:31-35.
36.
UelandPM, HustadS, SchneedeJ, et al. (2001) Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci, 22:195-201.
37.
van Huis-TanjaLH, GelderblomH, PuntCJ, et al. (2013) MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. Pharmacogenet Genomics, 23:208-218.
38.
WallaceBD, WangH, LaneKT, et al. (2010) Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science, 330:831-835.
39.
WaltherA, JohnstoneE, SwantonC, et al. (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer, 9:489-499.
40.
WeisbergI, TranP, ChristensenB, et al. (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab, 64:169-172.
41.
YangL, LiuL, WangJ, et al. (2011) Polymorphisms in folate-related genes: impact on risk of adult acute lymphoblastic leukemia rather than pediatric in Han Chinese. Leuk Lymphoma, 52:1770-1776.
42.
ZarateR, RodriguezJ, BandresE, et al. (2010) Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer, 102:987-994.
